DIRS.INFO The most relevant business & tech news

Stars from Hollywood's golden age are being reborn through celebrity estate AI voice cloning deals, a sign of how some of the "Wild West" concerns about unauthorized AI impersonation are being addressed by new business models. Safeguards include active moderation of content, accountability enforceable with bans, and special provisions for safeguarding the impact of AI voice on the 2024 election. Among the current generation of actors, there remains significant anxiety surrounding the use of AI in generating voice content. Voice actors for video games have raised concerns, and last year's film and television strike had significant roots in anxieties over the use of AI. AI voice licensing could alleviate workload for voice actors, he added, without supplanting them, as they "intercede in the process by focusing on offering correction or enhancement to ineffable aspects such as intonation, warmth, and emphasis, which still present challenges."

Persons: Burt Reynolds, Andreessen Horowitz, Judy Garland, James Dean, Sir Laurence Olivier, ElevenLabs, Sam Sklar, Scarlett Johansson, " Sklar, Frito, Tom Waits soundalike, Waits, Lovo, Steve Cohen, Pollock, Cohen, Bette Davis, Sklar, Nauman Dawalatabad, Dawalatabad, Michele Cobb Organizations: Golden Globe, Beverly Hilton Hotel, Sequoia, New York Times, Washington Post, Disney, Google, Apple, MIT Computer Science, Artificial Intelligence, Audio Publishers Association, CNBC

☆ They claim AI stole their voices. Now they’re suing
▼ + stars: | 2024-05-17 | by ( Clare Duffy | ) edition.cnn.com time to read: +3 min

Now, Lehrman, along with fellow voice actor Linnea Sage, is suing AI firm Lovo for allegedly commissioning them for voice projects under false pretenses in order to create and sell AI-generated versions of their voices. The Berkeley, California based tech company advertises AI-generated voice technology to be used in marketing, education and product demos. Then in June 2023, Lehrman claims he heard his voice being used on a podcast about the dangers of AI technologies. Sage says she later also discovered her voice in a YouTube video: a recording of a Lovo investor presentation demonstrating its technology. They are voices stolen by LOVO and marketed by LOVO under false pretenses,” the complaint states.

Persons: Paul Lehrman, Linnea Sage, Lovo, Sage, ” Lovo, Lehrman, he’d, LOVO Organizations: New, New York CNN —, Court, New York Times Locations: New York, Berkeley, California, Southern

☆ Here are Friday's biggest analyst calls: Amazon, Apple, Tesla, Royal Caribbean, Intel, Hasbro & more
▼ + stars: | 2023-04-28 | by ( Michael Bloom | ) www.cnbc.com time to read: +5 min

Here are Friday's biggest calls on Wall Street: Bank of America upgrades Hasbro to neutral from underperform Bank of America said it sees resilient demand for Hasbro . Goldman Sachs reiterates Amazon as buy Goldman said it's standing by the stock after its robust earnings report Thursday. " Benchmark upgrades Intel to buy from hold Benchmark said in its upgrade of Intel that the worst is already baked in. Bank of America upgrades Pilgrim's Pride to buy from neutral Bank of America said in its upgrade of the poultry company that the worst is behind it. Morgan Stanley reiterates Apple as overweight Morgan Stanley said it's still bullish on Apple shares heading into earnings next week.

☆ Shares of this under-the-radar cell therapy stock are set to double, says Baird
▼ + stars: | 2023-03-07 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Shares of biotech company bluebird bio should double in the coming year, thanks to its treatments for sickle cell disease, a genetic blood disease and a rare genetic brain condition, according to Baird. The Wall Street firm initiated coverage of the stock on Monday with an outperform rating and $10 price target, which implies 104% upside from Monday's close. The company's management said in January that 40 patients had initiated benefits verification for Zynteglo during the last three months of 2022. Lastly, Baird expects the use of bluebird's Skysona treatment for CALD, which was approved in September 2022, to increase significantly in the coming years. The under-the-radar stock, which has a market cap of over $500 million, is down about 29% this year, as of Monday's close.

Search resuls for: "LOVO"

4 mentions found